摘要
目的探析利培酮对精神分裂症患者的应用效果。方法60例精神分裂症患者为研究对象,以治疗方案不同分为对照组和干预组,每组30例。对照组使用常规药物治疗,干预组在对照组基础上增加利培酮治疗。对比两组不良反应发生率、精神症状评分、社会支持度评分、阳性与阴性症状量表(PANSS)评分和生活质量评分。结果干预组不良反应发生率3.33%低于对照组的20.00%(P<0.05)。干预组敌对猜疑、激惹性、焦虑抑郁、思维障碍、行为紊乱、活力缺乏、自知力缺乏评分分别为(2.24±0.24)、(1.52±0.15)、(1.62±0.16)、(1.25±0.12)、(1.41±0.14)、(2.24±0.22)、(4.64±0.42)分,低于对照组的(3.85±0.35)、(2.42±0.24)、(1.88±0.18)、(2.85±0.25)、(2.68±0.26)、(2.46±0.24)、(5.41±0.53)分(P<0.05)。治疗后,干预组主观支持、客观支持、支持利用度评分及总分分别为(16.95±1.64)、(10.85±0.88)、(8.85±0.76)、(36.65±3.31)分,均高于对照组的(15.96±1.59)、(6.61±0.63)、(6.86±0.68)、(29.43±2.95)分(P<0.05)。治疗8周,干预组阳性症状、阴性症状、一般精神病理症状评分及总分均低于对照组(P<0.05)。治疗后,干预组躯体功能、情绪职能、生理功能、社会功能评分均高于对照组(P<0.05)。结论利培酮可改善精神分裂症患者的精神症状,提高社会支持度及生活质量,且不良反应发生率低,值得在临床实践中推广应用。
Objective To explore the application effect of risperidone on schizophrenia patients.Methods 60 patients with schizophrenia as the research subjects and divided into a control group and an intervention group according to different treatment plans,with 30 cases in each group.The control group received conventional drug treatment,and the intervention group received risperidone treatment on the basis of the control group.Comparison of incidence of adverse reactions,mental symptom scores,social support scores,Positive and Negative Symptom Scale(PANSS)scores and quality of life scores between the two groups.Results The incidence of adverse reactions 3.33%in the intervention group was lower than 20.00%in the control group(P<0.05).The scores of hostility and suspicion,irritability,anxiety and depression,thinking disorder,behavioral disorder,lack of vitality and lack of self-awareness in the intervention group were(2.24±0.24),(1.52±0.15),(1.62±0.16),(1.25±0.12),(1.41±0.14),(2.24±0.22)and(4.64±0.42)points,which were lower than those in the control group[(3.85±0.35),(2.42±0.24),(1.88±0.18),(2.85±0.25),(2.68±0.26),(2.46±0.24),and(5.41±0.53)points](P<0.05).After treatment,the scores of subjective support,objective support,support utilization and the total score of the intervention group were(16.95±1.64),(10.85±0.88),(8.85±0.76),and(36.65±3.31)points,which were higher than those of the control group[(15.96±1.59),(6.61±0.63),(6.86±0.68),and(29.43±2.95)points](P<0.05).After 8 weeks of treatment,the scores of positive symptoms,negative symptoms,general psychopathological symptoms and total score in the intervention group were all lower than those in the control group(P<0.05).After treatment,the scores of physical function,emotional function,physiological function,and social function in the intervention group were higher than those in the control group(P<0.05).Conclusion Risperidone can improve the mental symptoms of patients with schizophrenia,increase social support and quality of life,and has a low incidence of adverse reactions,making it worthy of promotion and application in clinical practice.
作者
卢冬梅
LU Dong-mei(Ganyu District Psychiatric Hospital,Lianyungang 222100,China)
出处
《中国现代药物应用》
2025年第20期85-88,共4页
Chinese Journal of Modern Drug Application
关键词
利培酮
精神分裂症
认知功能
Risperidone
Schizophrenia
Cognitive function
